Literature DB >> 18715245

Experiences and expectations of women with urogenital prolapse: a quantitative and qualitative exploration.

S Srikrishna1, D Robinson, L Cardozo, R Cartwright.   

Abstract

OBJECTIVE: To explore the expectations and goals of women undergoing surgery for urogenital prolapse using both a quantitative quality of life approach exploring symptom bother and a qualitative interview-based approach exploring patient goals and expectations.
DESIGN: Prospective observational study.
SETTING: Tertiary referral centre for urogynaecology. POPULATION: Forty-three women with symptomatic pelvic organ prolapse were recruited from the waiting list for pelvic floor reconstructive surgery.
METHODS: All women were assessed with a structured clinical interview on an individual basis. The data obtained were transcribed verbatim and then analysed thematically based on the grounded theory. Individual codes and subcodes were identified to develop a coding framework. The prolapse quality-of-life (pQoL) questionnaire was used to determine the impact of pelvic organ prolapse on the woman's daily life. We arbitrarily classified 'bother' as minimal, mild, moderate and marked if scores ranged from 0 to 25, 25-50, 50-75 and 75-100, respectively. The degree of prolapse was objectively quantified using the pelvic organ prolapse quantification (POP-Q) system. Quantitative data were analysed using SPSS. Ethical approval was obtained from the Kings College Hospital Ethics Committee. MAIN OUTCOME MEASURES: Quantitative data from POP-Q, subjective data from pQoL, qualitative data based on the structured clinical interview.
RESULTS: Forty-three women were recruited over the first 1 year of the study. Their mean age was 56 years (range 36-78) and mean parity was 2 (range 0-6). The mean ordinal stage of the prolapse was 2 (range stages 1-4). Quantitative analysis of the pQoL data suggested that the main domains affected were prolapse impact on life (mean score 74.71) and personal relationships (mean score 46.66). Qualitative analysis based on the clinical interview suggested that these women were most affected by the actual physical symptoms of prolapse (bulge, pain and bowel problems) as well by the impact prolapse has on their sexual function.
CONCLUSIONS: While disease-specific QoL questionnaires allow broad comparisons to be made assessing patient bother, they may lack the sensitivity to assess individual symptoms. A qualitative approach may individualize patient care and ultimately improve patient satisfaction and overall outcome when treating women complaining of urogenital prolapse.

Entities:  

Mesh:

Year:  2008        PMID: 18715245     DOI: 10.1111/j.1471-0528.2008.01842.x

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  15 in total

1.  Validity and reliability of patient selected goals as an outcome measure in overactive bladder.

Authors:  Rufus Cartwright; Sushma Srikrishna; Linda Cardozo; Dudley Robinson
Journal:  Int Urogynecol J       Date:  2011-01-29       Impact factor: 2.894

2.  An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for reporting outcomes of surgical procedures for pelvic organ prolapse.

Authors:  Philip Toozs-Hobson; Robert Freeman; Matthew Barber; Christopher Maher; Bernard Haylen; Stavros Athanasiou; Steven Swift; Kristene Whitmore; Gamal Ghoniem; Dirk de Ridder
Journal:  Int Urogynecol J       Date:  2012-05       Impact factor: 2.894

3.  The inter-system association between the simplified pelvic organ prolapse quantification system (S-POP) and the standard pelvic organ prolapse quantification system (POPQ) in describing pelvic organ prolapse.

Authors:  Jittima Manonai; Lone Mouritsen; Paulo Palma; Oscar Contreras-Ortiz; Jeffrey E Korte; Steven Swift
Journal:  Int Urogynecol J       Date:  2010-10-09       Impact factor: 2.894

4.  Pelvic organ prolapse: a disease of silence and shame.

Authors:  Gena C Dunivan; Jennifer T Anger; Alexandriah Alas; Cecilia Wieslander; Claudia Sevilla; Stephanie Chu; Sally Maliski; Biatris Barrera; Karyn Eiber; Rebecca G Rogers
Journal:  Female Pelvic Med Reconstr Surg       Date:  2014 Nov-Dec       Impact factor: 2.091

5.  Gaining the patient perspective on pelvic floor disorders' surgical adverse events.

Authors:  Gena C Dunivan; Andrew L Sussman; J Eric Jelovsek; Vivian Sung; Uduak U Andy; Alicia Ballard; Sharon Jakus-Waldman; Cindy L Amundsen; Christopher J Chermansky; Carla M Bann; Donna Mazloomdoost; Rebecca G Rogers
Journal:  Am J Obstet Gynecol       Date:  2018-10-26       Impact factor: 8.661

6.  The S.A.C.S. (Satisfaction-Anatomy-Continence-Safety) score for evaluating pelvic organ prolapse surgery: a proposal for an outcome-based scoring system.

Authors:  Luigi Mearini; Alessandro Zucchi; Elisabetta Nunzi; Manuel Di Biase; Vittorio Bini; Elisabetta Costantini
Journal:  Int Urogynecol J       Date:  2015-02-26       Impact factor: 2.894

7.  Do women with overactive bladder have realistic expectations for therapy?

Authors:  Arasee Renganathan; Dudley Robinson; Linda Cardozo; Sushma Srikrishna; Rufus Cartwright
Journal:  Int Urogynecol J       Date:  2010-04       Impact factor: 2.894

8.  Goal attainment after treatment in patients with symptomatic pelvic organ prolapse.

Authors:  Mamta M Mamik; Rebecca G Rogers; Clifford R Qualls; Yuko M Komesu
Journal:  Am J Obstet Gynecol       Date:  2013-06-13       Impact factor: 8.661

9.  'A hidden disorder until the pieces fall into place'--a qualitative study of vaginal prolapse.

Authors:  Mojgan Pakbaz; Margareta Persson; Mats Löfgren; Ingrid Mogren
Journal:  BMC Womens Health       Date:  2010-05-24       Impact factor: 2.809

10.  Validation of the Spanish-language version of the Prolapse Quality of Life questionnaire in Chilean women.

Authors:  Claudia Flores-Espinoza; Alejandra Ximena Araya; Javier Pizarro-Berdichevsky; Vera Santos; Montserrat Ferrer; Olatz Garin; Steven Swift; Alessandro G Digesu
Journal:  Int Urogynecol J       Date:  2014-09-16       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.